Shire (NASDAQ:SHPG) had its price objective increased by stock analysts at B. Riley to $200.00 in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. B. Riley’s price objective would indicate a potential upside of 24.12% from the stock’s current price.
Several other analysts have also recently weighed in on the stock. Zacks Investment Research cut shares of Shire from a “hold” rating to a “sell” rating in a research note on Tuesday, January 2nd. Bank of America increased their price target on shares of Shire from $236.00 to $237.00 and gave the company a “buy” rating in a research note on Monday, February 5th. Cowen set a $225.00 price target on shares of Shire and gave the company a “buy” rating in a research note on Friday, January 5th. BidaskClub cut shares of Shire from a “sell” rating to a “strong sell” rating in a research note on Friday, January 26th. Finally, Cantor Fitzgerald set a $222.00 price target on shares of Shire and gave the company a “buy” rating in a research note on Wednesday, December 27th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $204.64.
Shire stock traded down $1.40 during trading hours on Thursday, hitting $161.14. 8,886,538 shares of the stock were exchanged, compared to its average volume of 1,413,853. The company has a current ratio of 0.97, a quick ratio of 0.55 and a debt-to-equity ratio of 0.46. The stock has a market capitalization of $47,130.30, a price-to-earnings ratio of 10.63, a P/E/G ratio of 1.22 and a beta of 1.31. Shire has a 12 month low of $123.73 and a 12 month high of $192.15.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $3.37 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $3.58 by ($0.21). Shire had a return on equity of 14.19% and a net margin of 28.17%. equities research analysts predict that Shire will post 15.22 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in SHPG. Boston Partners lifted its holdings in Shire by 60.9% in the fourth quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after buying an additional 886,572 shares during the period. ING Groep NV lifted its holdings in Shire by 9,043.1% in the fourth quarter. ING Groep NV now owns 524,537 shares of the biopharmaceutical company’s stock valued at $81,366,000 after buying an additional 518,800 shares during the period. FNY Partners Fund LP lifted its holdings in Shire by 346.6% in the fourth quarter. FNY Partners Fund LP now owns 474,460 shares of the biopharmaceutical company’s stock valued at $73,598,000 after buying an additional 368,214 shares during the period. Brandywine Global Investment Management LLC acquired a new position in Shire in the fourth quarter valued at approximately $41,763,000. Finally, Snow Capital Management LP acquired a new position in Shire in the fourth quarter valued at approximately $33,891,000. Institutional investors and hedge funds own 19.58% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Shire (SHPG) Price Target Raised to $200.00” was first reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/19/shire-shpg-price-target-raised-to-200-00.html.
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells specialist medicines for people with rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.